Cargando…
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading worldwide, development of antibodies and vaccines to confer broad and protective activity is a global priority. Here, we report on the identification of a special group of nanobodies from immunized alpaca with potency agai...
Autores principales: | Li, Mingxi, Ren, Yifei, Aw, Zhen Qin, Chen, Bo, Yang, Ziqing, Lei, Yuqing, Cheng, Lin, Liang, Qingtai, Hong, Junxian, Yang, Yiling, Chen, Jing, Wong, Yi Hao, Wei, Jing, Shan, Sisi, Zhang, Senyan, Ge, Jiwan, Wang, Ruoke, Dong, Jay Zengjun, Chen, Yuxing, Shi, Xuanling, Zhang, Qi, Zhang, Zheng, Chu, Justin Jang Hann, Wang, Xinquan, Zhang, Linqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792944/ https://www.ncbi.nlm.nih.gov/pubmed/36575191 http://dx.doi.org/10.1038/s41467-022-35642-2 |
Ejemplares similares
-
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022) -
Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022) -
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022) -
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022) -
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)